The development of medical genetic services is not considered a priority in developing nations. However, many such countries are presently undergoing an epidemiological transition resulting in genetic disorders and birth defects becoming conditions that are attaining public health significance. South Africa is one such country. This paper documents the development, patient profile and experience gained in trying to establish a primary health care genetic/disability service in the country’s rural Northern Province.

1.
WHO Advisory Group: Community Approaches to Control of Hereditary Diseases. Geneva, WHO, 1985 (HDP/WG/85.10).
2.
Modell B, Modell M: Towards a Healthy Baby: Congenital Disorders and the New Genetics in Primary Health Care. Oxford, Oxford University Press, 1992.
3.
Penchaszadeh VB: Medical Genetic Services in Latin America. Geneva, WHO, 1998, (WHO/HGN/CON/MGS/98.4).
4.
Alwan A, Modell B: Community Control of Genetic and Congenital Disorders. EMRO Technical Publication Series 24. Alexandria, WHO Eastern Mediterranean Regional Office, 1997.
5.
WHO Scientific Group: Control of Hereditary Diseases. WHO Technical Report Series 865. WHO, Geneva, 1996.
6.
Christianson A, Gericke GS, Venter PA, du Toit JL: Genetics, primary health care and the Third World. S Afr Med J 1995;85:6–7.
7.
Delport SD, Christianson AL, van den Berg HJS, Wolmarans L, Gericke GS: Congenital anomalies in black South African liveborn neonates at an urban academic hospital. S Afr Med J 1995;85:11–15.
8.
Venter PA, Christianson AL, Hutamo CM, Makhura MP, Gericke GS: Congenital anomalies in rural black South African neonates – a silent epidemic? S Afr Med J 1995;85:15–20.
9.
Jenkins T: Medical genetics in South Africa. J Med Genet 1990;27:760–779.
10.
Department of National Health and Population Development: Health and Population Related Indicators per Province in South Africa. Pretoria, 1994.
11.
African National Congress. A National Health Plan for South Africa. Maseru, Bahr Mapping and Printing, 1994.
12.
Beighton P, Botha MC: Inherited disorders in the black population of southern Africa. Part I. Historical and demographic background; genetic haematological conditions. S Afr Med J 1986;69:247–249.
13.
Beighton P, Botha MC: Inherited disorders in the black population of southern Africa. Part II. Gene disorders. S Afr Med J 1986;69:293–296.
14.
Beighton P, Botha MC: Inherited disorders in the black population of southern Africa. Part III. Multifactorial, chromosomal and congenital conditions. S Afr Med J 1986;69:375–377.
15.
Ijsselmuiden CB, Lewis M, de Swart R: Rubella serology in the northern Transvaal. S Afr J Epidemiol 1986;1:79–83.
16.
Viljoen D: Fetal alcohol syndrome (editorial). S Afr Med J 1999;89:958–960.
17.
Zieff S, Nelson MM: Six years’ experience in a children’s hospital genetic clinic. S Afr Med J 1978;54:639–642.
18.
Christianson AL: Down syndrome in black South African infants and children – clinical features and delayed diagnosis. S Afr Med J 1997;87:992–995.
19.
Pelser J: Knowledge and Attitudes of South African Women to Prenatal Diagnosis; MSc thesis, University of Pretoria, South Africa, 1998.
20.
Viljoen D, Oosthuizen C, van der Westhuizen S: Patient attitudes to prenatal screening and termination of pregnancy at Groote Schuur Hospital. A two year prospective study. East Afr Med J 1996;73:327–329.
21.
Viljoen D, Beighton P, Hitzeroth H: Medical genetics in primary health care (editorial). S Afr Med J 1995;85:1–3.
22.
Penchaszadeh VB: Genetics and public health. Bull Pan Am Health Organ 1994;28:62–72.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.